|
Actimed Therapeutics Ltd (Actimed), a UK-based clinical-stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle-wasting disorders, announces that the Japan Patent Office (JPO) has granted a new composition of matter patent for S-pindolol benzoate (ACM-001.1), further strengthening the global intellectual property estate of the company.
The Japanese patent provides broad protection relating to S-pindolol benzoate and its pharmaceutically acceptable forms, extending coverage beyond prior patents and complementing existing grants in the US and Europe. The protection in Japan encompasses the composition of matter for S-pindolol benzoate and is not restricted to specific therapeutic indications, ensuring long-term exclusivity for a wide range of potential clinical applications, including but not limited to cancer cachexia and other muscle-wasting conditions.
Robin Bhattacherjee, Actimed CEO, commented: “I am very pleased to announce the grant of this important patent in Japan, one of the world’s largest pharmaceutical markets. This award significantly strengthens our global IP position for S-pindolol benzoate and underscores the breadth of protection that we have secured for our lead compound. We continue to progress S-pindolol benzoate through clinical development, including the ongoing PROACT phase 2a programme investigating it’s potential to reduce muscle-wasting in obese patients when used in combination with a GLP-1 receptor agonist. Robust patent coverage in key territories is a cornerstone of our strategy to bring innovative muscle-preserving therapies to patients who need them most.”
The newly granted Japanese patent joins a growing IP portfolio for Actimed, which includes multiple composition of matter and crystalline form patents already issued in the US and Europe. Together, these patents provide comprehensive protection for S-pindolol benzoate, a pro-anabolic and anti-catabolic transforming agent (ACTA) with a unique multi-modal mechanism of action targeting several key pathways involved in muscle wasting and cachexia.
|